Limits...
Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia.

Deguchi K, Liu N, Liu W, Omote Y, Kono S, Yunoki T, Deguchi S, Yamashita T, Ikeda Y, Abe K - J. Neurosci. Res. (2014)

Bottom Line: The number of pericytes and the overlap with NAGO decreased with tPA but recovered with edaravone 4 days after tMCAO with proliferation.Thus, tPA treatment damaged pericytes, resulting in the detachment from astrocytes and a decrease in glial cell line-derived neurotrophic factor secretion.However, treatment with edaravone greatly improved tPA-induced damage to pericytes.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

Show MeSH

Related in: MedlinePlus

A: Fluorescent immunohistochemistry of PDGFRβ-positive pericytes (a–d, red), NAGO-positive endothelial cells (e–h, green), merged images (i–l) with their high magnification images (m–p) in the cerebral cortex of the sham control (SC) and the border zone of ischemic regions at 1, 4, and 14 days after tMCAO. B: Quantitative coverage ratio of pericytes to endothelial cells shows a transient reduction (1 day) and overshoot recovery (4 days) after tMCAO. C: Western blot analysis shows an increase of PDGFRβ (210 kDa) level at 4 days and 7 days. *P < 0.05 vs. SC, **P < 0.01 vs. SC. ##P < 0.01 vs. 1 day. Scale bars = 100 μm in l (applies to a–l); 20 μm in p (applies to m–p).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263311&req=5

fig01: A: Fluorescent immunohistochemistry of PDGFRβ-positive pericytes (a–d, red), NAGO-positive endothelial cells (e–h, green), merged images (i–l) with their high magnification images (m–p) in the cerebral cortex of the sham control (SC) and the border zone of ischemic regions at 1, 4, and 14 days after tMCAO. B: Quantitative coverage ratio of pericytes to endothelial cells shows a transient reduction (1 day) and overshoot recovery (4 days) after tMCAO. C: Western blot analysis shows an increase of PDGFRβ (210 kDa) level at 4 days and 7 days. *P < 0.05 vs. SC, **P < 0.01 vs. SC. ##P < 0.01 vs. 1 day. Scale bars = 100 μm in l (applies to a–l); 20 μm in p (applies to m–p).

Mentions: Color panels in Figure 1 show the peri-ischemic brain regions. PDGFRβ-positive pericyte (red) partially overlapped (merged, yellow) with NAGO-positive endothelial cells (green). The coverage of PDGFRβ-positive pericytes with NAGO-positive endothelial cells was significantly reduced at 1 day after tMCAO (54.0% ± 2.2%, P < 0.01 vs. SC) compared with that of SC (61.7% ± 2.7%) and then increased significantly at 4 days (69.9% ± 1.3%, P < 0.01 vs. SC; Fig. 1B).


Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia.

Deguchi K, Liu N, Liu W, Omote Y, Kono S, Yunoki T, Deguchi S, Yamashita T, Ikeda Y, Abe K - J. Neurosci. Res. (2014)

A: Fluorescent immunohistochemistry of PDGFRβ-positive pericytes (a–d, red), NAGO-positive endothelial cells (e–h, green), merged images (i–l) with their high magnification images (m–p) in the cerebral cortex of the sham control (SC) and the border zone of ischemic regions at 1, 4, and 14 days after tMCAO. B: Quantitative coverage ratio of pericytes to endothelial cells shows a transient reduction (1 day) and overshoot recovery (4 days) after tMCAO. C: Western blot analysis shows an increase of PDGFRβ (210 kDa) level at 4 days and 7 days. *P < 0.05 vs. SC, **P < 0.01 vs. SC. ##P < 0.01 vs. 1 day. Scale bars = 100 μm in l (applies to a–l); 20 μm in p (applies to m–p).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263311&req=5

fig01: A: Fluorescent immunohistochemistry of PDGFRβ-positive pericytes (a–d, red), NAGO-positive endothelial cells (e–h, green), merged images (i–l) with their high magnification images (m–p) in the cerebral cortex of the sham control (SC) and the border zone of ischemic regions at 1, 4, and 14 days after tMCAO. B: Quantitative coverage ratio of pericytes to endothelial cells shows a transient reduction (1 day) and overshoot recovery (4 days) after tMCAO. C: Western blot analysis shows an increase of PDGFRβ (210 kDa) level at 4 days and 7 days. *P < 0.05 vs. SC, **P < 0.01 vs. SC. ##P < 0.01 vs. 1 day. Scale bars = 100 μm in l (applies to a–l); 20 μm in p (applies to m–p).
Mentions: Color panels in Figure 1 show the peri-ischemic brain regions. PDGFRβ-positive pericyte (red) partially overlapped (merged, yellow) with NAGO-positive endothelial cells (green). The coverage of PDGFRβ-positive pericytes with NAGO-positive endothelial cells was significantly reduced at 1 day after tMCAO (54.0% ± 2.2%, P < 0.01 vs. SC) compared with that of SC (61.7% ± 2.7%) and then increased significantly at 4 days (69.9% ± 1.3%, P < 0.01 vs. SC; Fig. 1B).

Bottom Line: The number of pericytes and the overlap with NAGO decreased with tPA but recovered with edaravone 4 days after tMCAO with proliferation.Thus, tPA treatment damaged pericytes, resulting in the detachment from astrocytes and a decrease in glial cell line-derived neurotrophic factor secretion.However, treatment with edaravone greatly improved tPA-induced damage to pericytes.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

Show MeSH
Related in: MedlinePlus